New iPSC Lines Added in 2022

02/2023

Induced pluripotent stem cells (iPSCs) offer hope to patients and promise to scientists due to their potential in disease pathology research and highly targeted therapies to improve health outcomes.

Our team has the core capabilities to maintain, characterize, bank, and distribute the highest quality iPSCs and our laboratories operate under the most stringent ISO 9001:2015 certified standard operating procedures, including the performance of quality control testing and assessment of pluripotency.

Below is the list of all new iPSC lines that were added to the Coriell biobank in 2022.

ID number Diagnosis
AG28346 Non-Wound Healing Phenotype
GM28374 Neuroaxonal Dystrophy, Infantile
GM28227 Neiman Pick Type C1
GM28229 Glycogen Storage Disease Type II
AG28369 Non-Wound Healing Phenotype
AG28462 Rothmund-Thomson Syndrome
GM28259 Tay Sachs Disease
AG28336 Parkinson Disease
GM28404 Apparently Healthy
GM28383 Scheie Syndrome
GM28385 Fibrodysplasia Ossificans Progressiva
AG28409 Xeroderm Pigmentosum
GM28558 Alagille Syndrome 1
GM27620 Rett Syndrome, Congenital Variant (FOXG1)
GM28380 Ceroid lipofuscinosis Neuronal 2, Late infantile
GM28559 Alagille Syndrome 1
GM27624 Rett Syndrome, Congenital Variant (FOXG1)
GM28589 Cerebral Creatine Deficiency Syndrome 3
GM28622 Glycogen Storage Disease Type II
AG28599 Parkinson Disease
GM28399 Neuropathy, Hereditary Sensory and Autonomic, Type III
GM28575 Rett Syndrome, Congenital Variant (FOXG1)
GM28576 Rett Syndrome, Congenital Variant (FOXG1)
GM28577 Rett Syndrome, Congenital Variant (FOXG1)
GM28578 Rett Syndrome, Congenital Variant (FOXG1)
AG28585 Cockayne Syndrome Type A
GM28603 Zinc-finger C4H2 Deficiency ZC4H2
AG28851 Apparently Healthy
AG28869 Apparently Healthy
GM28862 Leigh Syndrome

Other News